[Sympathetic ophthalmia 50 years after penetrating injury. A case report].
BACKGROUND
Sympathetic ophthalmia is a rare form of autoimmune uveitis and manifests in 90% of cases within the first year after penetrating injuries or surgical interventions.


METHODS
In the present case the sympathetic ophthalmia started 50 years after a penetrating injury by a shell splinter. The injured eye was amaurotic and phthitic and the sympathizing eye showed an anterior uveitis. After an initial treatment with local and systemic corticosteroids the uveitis improved. The clinical diagnosis of sympathetic ophthalmia was made after a second inflammation course with substantial visual loss and subtotal chorioidal detachment. After enucleation of the exciting eye the diagnosis was confirmed by histological examination. An immunosuppressive therapy including azathioprine and cyclosporine became necessary to control the uveitis.


RESULTS
After enucleation the corticosteroid treatment was not sufficient. Additional therapy with azathioprine resulted in a recovery of the symptoms but had to be stopped because of adverse reactions. The alternative therapy by means of cyclosporine was tolerated well, but dose reduction was difficult because of recurrences. After a 30 month lasting cyclosporine therapy the patient shows stabile results since 6 months with visual acuity of 20/30.


CONCLUSIONS
The present case report demonstrates that a delayed onset of sympathetic ophthalmia 50 years after initial trauma may occur but can be controlled by an immediate, high dose immunotherapy.
Hellmund
K
K
Augenklinik im Universitätsklinikum C. G. Carus, TU Dresden.
Frühauf
A
A
Seiler
T
T
Naumann
G O
GO
D000368:Aged; D001327:Autoimmune Diseases / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D001379:Azathioprine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000008:administration & dosage; D015353:Eye Enucleation; D015807:Eye Injuries, Penetrating / Q000150:complications* / Q000276:immunology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D009879:Ophthalmia, Sympathetic / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine